NIKKEI 225
38,048.00 +86.20 (+0.23%) HANG SENG
16,398.22 +146.38 (+0.90%) CRUDE OIL
82.75 +0.06 (+0.07%) GOLD FUTURES
2,385.80 -2.60 (-0.11%) DOW
37,753.31 -45.66 (-0.12%) Bitcoin GBP
49,495.63 -1,795.99 (-3.50%)
CareDx, Inc (CDNA)
After hours:
| Previous close | 7.85 |
| Open | 8.00 |
| Bid | 8.19 x 100 |
| Ask | 8.34 x 100 |
| Day's range | 7.91 - 8.42 |
| 52-week range | 4.80 - 12.93 |
| Volume | |
| Avg. volume | 908,419 |
| Market cap | 428.726M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
BRISBANE, Calif., April 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.
- Business Wire
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
BRISBANE, Calif., April 09, 2024--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx’s cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th An
- Business Wire
CareDx Appoints Bryan Riggsbee to Its Board of Directors
BRISBANE, Calif., March 11, 2024--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx’s Board of Directors, effective March 11, 2024.
